[Pulmonary edema during tocolytic treatment (author's transl)]

Area of Science:

• Obstetrics and Gynecology
• Pharmacology
• Critical Care Medicine

Context:

• Tocolytic therapy using Beta 2-Sympathomimetic drugs is common in managing preterm labor.
• Pulmonary edema is an occasional but serious adverse event associated with this treatment.
• The exact mechanism leading to pulmonary edema during tocolytic treatment remains unclear.

Purpose:

• To investigate the pathogenesis of pulmonary edema in patients receiving Beta 2-Sympathomimetic drugs for tocolysis.
• To identify risk factors and patient groups susceptible to developing pulmonary edema.
• To propose management strategies for preventing and treating this complication.

Summary:

• Beta 2-Sympathomimetic tocolytic treatment leads to rapid water retention within 48 hours, evidenced by weight gain and decreased fluid/sodium excretion.
• This iatrogenic fluid overload, especially when combined with physiological pregnancy-related water retention or other risk factors like pre-eclampsia, can precipitate hypervolemia and pulmonary edema.
• The study discusses the underlying pathophysiology and outlines recommendations for clinical management, including identifying 10 high-risk patient groups requiring vigilant monitoring.

Impact:

• Highlights the risk of pulmonary edema associated with Beta 2-Sympathomimetic tocolysis, emphasizing the need for careful patient selection and monitoring.
• Provides a framework for understanding the fluid dynamics and potential complications, guiding clinical practice in managing preterm labor.
• Informs healthcare providers about high-risk patient profiles, enabling proactive interventions to mitigate the incidence of tocolytic-induced pulmonary edema.